U.S. Diabetes Therapies and Complications Markets

1
U.S. Diabetes Therapies and Complications Markets

• The growing demand and the introduction of
  technologically advanced products is likely to
  transform this market into a highly lucrative and
  profitable segment within the pharmaceuticals
  industry.

Pharmaceuticals Analyst Team Frost Sullivan
2
Industry Trends

• Increase in diagnosed diabetic population
  inflates market potential.
• Introduction of technologically superior
  therapies increases cost of therapy and drives
  revenues.
• Entry of more number of players and cross-segment
  moves intensifies leadership strife.
• Non-invasive insulin technologies to cause
  increase in the use of insulin by the diabetics.
• Launch of diabetes complications products to
  affect clinical management of diabetes and the
  market landscape.

3
Key Features

• Frost Sullivan provides
• Detailed insights into recent developments and
  trends
• Drivers, restraints, challenges, and strategic
  recommendations
• Analyst insights on hot topics and emerging
  applications
• in the pharmaceuticals market
• Market sizing and competitive analysis
• Market forecasts and opportunity analysis

4
What We Offer

• Coverage The United States
• Proven methodology encompassing extensive primary
  and secondary data and research
• Focused information and strategies that cover
  business and technology issues
• Credible data and analysis highlighting industry
  dynamics
• Winning strategies to help you create precise
  business plans

5
Who Will Benefit?

• Current Market Participants
• Find out how you compare to the competition
• Assess current and future drivers and restraints
• Determine and exploit new market share
  opportunities
• New Entrants
• Analyze challenges associated with the industry
• Calculate time scales for strategy implementation
• Position yourself to capitalize on the markets
  unmet needs
• Investment Community
• Analyze long-term strategies of pharmaceutical
  companies
• Determine which participants will outperform the
  competition
• Assess attractiveness of investing in
  pharmaceutical market

6
Whats Included

• Insulin Therapies
• Oral Diabetes Medications
• Sulfonylureas
• Biguanides
• Alpha-Glucosidase Inhibitors (AGIs)
• Glitazones
• Meglitinides
• .Diabetes Complications Products
• Diabetic Nephropathy
• Diabetic Neuropathy
• Diabetic Retinopathy

7
Key Market Participants
Aerogen, Inc. Alizyme Plc. Alkermes, Inc.
Allergan, Inc. Alteon, Inc. Amylin
Pharmaceuticals, Inc. Anergen, Inc. Aradigm
Corp. Astra Zeneca Pharmaceuticals LP Aurogen,
Inc. Autoimmune, Inc. Aventis Pharmaceuticals,
Inc. Battelle Medical Products Bayer
Corp. Biobras S.A. BioSante Pharmaceuticals,
Inc. Biostratum, Inc. Bristol-Myers Squibb Co.
Calyx Therapeutics, Inc. Cangene Corp.
ConjuChem, Inc. CP Pharmaceuticals Ltd Dainippon
Pharmaceutical Co., Ltd. Diamyd Medical AB
Diosynth BV Dongbao Pharmaceuticals Ltd. Eli
Lilly and Co. EMD Pharmaceuticals Emisphere
Technologies, Inc. Epicept Corp. Ergo Science
Corp. Exocell, Inc. Flamel Technologies Fujisawa
Healthcare, Inc. Generex Biotechnology
Corp. Genpharm, Inc. GlaxoSmithkline Hoffmann-La
Roche, Inc. Inhale Therapeutic Systems, Inc.
8
Key Market Participants
Novo Nordisk Pharmaceuticals, Inc Organogenesis
Inc. Pfizer, Inc. Pharmacia Corp. Reddy US
Therapeutics, Inc. Sankyo Pharma, Inc. Scios,
Inc. Servier International Takeda
Pharmaceuticals North America, Inc. The
Institute of Diabetes Discovery The Quigley
Corp. Watson Laboratories, Inc. Wyeth
Pharmaceuticals Yamanouchi Pharma America, Inc.
Insmed, Inc. Isis Pharmaceuticals, Inc. Johnson
Johnson Pharmaceutical Research
Development Karo Bio AB Keryx Biopharmaceuticals,
Inc. Ligand Pharmaceuticals, Inc. Maxia
Pharmaceuticals, Inc. Merck Co.,
Inc. Metabolex, Inc. Neurocrine Biosciences,
Inc. Nexell Therapeutics, Inc. Nobex Corp.
Novartis Pharmaceuticals Corp.
9
For More Information

• Call toll free 877 GO FROST
• (877.463.7876)
• Fax toll free 888.690.3329
• Email myfrost_at_frost.com
• Visit www.frost.com